Immune Health and Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MD

Immune Health and Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MD

How PSA Responds to #ProstateCancer Treatment | #MarkScholzMD #AlexScholz #PCRIПодробнее

How PSA Responds to #ProstateCancer Treatment | #MarkScholzMD #AlexScholz #PCRI

Radiation, PSMA, Immune Therapy | Questions From The PCRI Mid-Year Update | Mark Scholz, MDПодробнее

Radiation, PSMA, Immune Therapy | Questions From The PCRI Mid-Year Update | Mark Scholz, MD

Active Surveillance in 2022 | Laurence Klotz, MD | PCRIПодробнее

Active Surveillance in 2022 | Laurence Klotz, MD | PCRI

Monitoring PSA After Radiation Therapy | Answering YouTube Comments #70 | Mark Scholz, MD | PCRIПодробнее

Monitoring PSA After Radiation Therapy | Answering YouTube Comments #70 | Mark Scholz, MD | PCRI

Promising Studies In Prostate Cancer | A 2021 ASCO Update | Mark Scholz, MDПодробнее

Promising Studies In Prostate Cancer | A 2021 ASCO Update | Mark Scholz, MD

Provenge, Keytruda, & Protecting Nerve Bundles From Radiation | Answering YouTube Comments #42Подробнее

Provenge, Keytruda, & Protecting Nerve Bundles From Radiation | Answering YouTube Comments #42

Immunotherapy In 2021, Mark Scholz, MD, Prostate Cancer Support Association of New MexicoПодробнее

Immunotherapy In 2021, Mark Scholz, MD, Prostate Cancer Support Association of New Mexico

Treatment for Few Metastases | Oligo-Metastases Disease | Mark Scholz, MD | PCRIПодробнее

Treatment for Few Metastases | Oligo-Metastases Disease | Mark Scholz, MD | PCRI

High PSA: Prostatitis or Prostate Cancer? | Mark Scholz, MD | PCRIПодробнее

High PSA: Prostatitis or Prostate Cancer? | Mark Scholz, MD | PCRI

Immunotherapy in 2022: Provenge, Keytruda, Car-T, and Leukine for Prostate Cancer | Mark Scholz, MDПодробнее

Immunotherapy in 2022: Provenge, Keytruda, Car-T, and Leukine for Prostate Cancer | Mark Scholz, MD

Treatments Gleason 3+4 & Gleason 4+3 Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MDПодробнее

Treatments Gleason 3+4 & Gleason 4+3 Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MD

What Is M0 Prostate Cancer and How Is It Identified? | Ask a Prostate Expert, Mark Scholz, MDПодробнее

What Is M0 Prostate Cancer and How Is It Identified? | Ask a Prostate Expert, Mark Scholz, MD

Radiation and Surgery Side Effects for Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MDПодробнее

Radiation and Surgery Side Effects for Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MD

PSMA/PET Scans: FDA Approved | Ask A Prostate Expert, Mark Scholz, MDПодробнее

PSMA/PET Scans: FDA Approved | Ask A Prostate Expert, Mark Scholz, MD

Focal Radiation, Antibiotics, & ED after Hormone Therapy, Ask a Prostate Expert, Mark Scholz, MD #12Подробнее

Focal Radiation, Antibiotics, & ED after Hormone Therapy, Ask a Prostate Expert, Mark Scholz, MD #12

An Overview of Gleason 3+4 & Gleason 4+3 Prostate Cancer | Ask A Prostate Expert, Mark Scholz, MDПодробнее

An Overview of Gleason 3+4 & Gleason 4+3 Prostate Cancer | Ask A Prostate Expert, Mark Scholz, MD

3 Future Prostate Cancer Treatment Advancements | Mark Scholz, MD & Mark Moyad, MD | 2021 PCRIПодробнее

3 Future Prostate Cancer Treatment Advancements | Mark Scholz, MD & Mark Moyad, MD | 2021 PCRI

Xofigo | How It Works, Side Effects, and More | Ask a Prostate Expert, Mark Scholz, MD | PCRIПодробнее

Xofigo | How It Works, Side Effects, and More | Ask a Prostate Expert, Mark Scholz, MD | PCRI

Comparing the Second Generation Hormone Therapies | Ask a Prostate Expert, Mark Scholz, MDПодробнее

Comparing the Second Generation Hormone Therapies | Ask a Prostate Expert, Mark Scholz, MD